Friedreich’s ataxia (FA) is an autosomal recessively inherited disease that occurs in Caucasians with an average prevalence far less common than the 1 in 200,000 threshold that is generally…
The malignant melanoma treatment landscape is dynamic and continues to undergo significant changes. Three immune checkpoint inhibitors including a dual checkpoint blockade regimen, four BRAF or MEK…
Gastric and gastroesophageal junction (GEJ) adenocarcinoma is characterized by poor prognosis. Japan has the highest incidence of gastric and GEJ adenocarcinoma among the markets under study,…
Angiogenesis inhibitors are the mainstay of the treatment of advanced renal cell carcinoma. However, the treatment algorithm is rapidly evolving driven by the approval of novel agents, including…
Colorectal cancer (CRC) affects several thousands of people in Brazil and Mexico. Once it metastasizes, the only available therapeutic options are premium-priced targeted agents and chemotherapy…
Schizophrenia and major depressive disorder (MDD) are disabling psychiatric conditions that are linked to a heavy economic and disease burden on society and patients as well as their caregivers…
Idiopathic pulmonary fibrosis (IPF), although a rare disease, is one of the most common interstitial lung diseases (ILDs) and is characterized by irreversible loss of lung function leading to high…
Biomarker-driven prescribing in oncology is playing an increasingly important role in various diseases, from indications in which its use is well entranced such as non-small-cell lung cancer (NSCLC…
The migraine market consists of a multitude of therapies that either acutely treat migraine attacks or serve as prophylactic treatment. Among acute antimigraine therapies, triptans and NSAIDs/…
The success of an anticancer therapy is not only dependent on the outcome of its pivotal trial, but also on that trial’s design, which is examined by the regulatory bodies, payers, and…
The type 2 diabetes therapy market will rapidly expand over our 2015-2025 study period, fueled by the disease’s increasing prevalence and a high unmet need for drugs that can effectively control…
The systemic lupus erythematosus (SLE) market in the United States is largely genericized and off-label. With the exception of Benlysta (IV)—which launched in 2011—no new drug has been approved…
Pancreatic cancer remains a deadly disease with limited treatment options. The current standards of treatment are mFOLFIRINOX and gemcitabine + Abraxane. Market growth over the forecast period to…
Type 2 diabetes (T2D) is a complex metabolic disorder characterized by a declining ability to produce or utilize insulin. The chronic and progressive nature of the disease, as well as its…
The positive symptoms of schizophrenia (e.g., hallucinations, delusions) are a symptom domain of schizophrenia that affects approximately 83% of the 3.2 million diagnosed prevalent cases of…